@Wasabibarako Look at the broader stem cell sector for your answers and CYP's inertia. Plenty of comparable US companies have faced even larger sell downs. CYP needs some good news on trials or other developments. Its simply the nature of speculative bio tech, the share prices often behave like decaying call options in effect. I do think you just saw a lot of end of US year tax selling on the biggest yearly SP500 decline since 2008. You may see a bounce in small caps (Russell Index in US) and bio-techs within that. An MSB resubmission soon might buoy the sector.
@Wasabibarako Look at the broader stem cell sector for your...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.015(9.68%) |
Mkt cap ! $38.41M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 17.0¢ | 15.5¢ | $47.10K | 289.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 23813 | 3 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |